GLPwatch

Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid

NCT04880005 · Recruiting

Last updated 2026-05-28

This trial tests a digital tool to help doctors and patients with type 2 diabetes work together to manage the condition in a general practice setting.

Status Recruiting Currently enrolling participants.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, single-blind treatment study
Participants 400 people Planned (estimated).
Who can join Ages 18–80 · all sexes
Timeline Started 2021-06 · est. completion 2025-12
Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT04880005 ↗

Description as written by the study sponsor.

The purpose of this project is to improve life of patients with type 2 diabetes through an IT-supported lifestyle and treatment intervention. The intervention is based on combining and adapting existing and effective elements into the IT system of the general practitioner. In this way we will integrate specialist supervised treatment in general practice, individual patient coaching, and improved information exchange and data mining. The DICTA intervention consists of two integrated components: a patient-directed eHealth lifestyle coaching program delivered via the LIVA application, and a clinician-directed CDS tool embedded into the EPJ system. 1. eHealth lifestyle coaching: Individuals with T2D in the intervention group will receive individualized digital coaching from a health coach through the LIVA application. PROs are shared with GPs and health staff via the EPJ, enabling tailored, data-driven lifestyle support. 2. CDS: GPs receive real-time, individualized, algorithm-based pharmacological treatment recommendations for managing T2D, hypertension, and hypercholesterolemia, as appropriate. This is expected to facilitate use, assure individually tailored solutions, optimize treatment effects, and strengthen patient engagement. The study is a randomized controlled trial (RCT). It will include 400 patients with newly diagnosed type 2 diabetes. The patients will receive either treatment based on the intervention or usual care. After one year, we will assess quality of life and cardiovascular risk factors in both groups and evaluate if one group has improved management of their type 2 diabetes compared to the other. If the intervention proves effective, implementation on a national scale is highly feasible, and the intervention could probably be adapted to other lifestyle-related chronic diseases in Denmark and in other countries.

Treatments tested

Main thing measuredChange in a binary indicator, composed by a composite endpoint of HbA1c, systolic blood pressure, low-density lipoprotein cholesterol, no smoking, and normal albuminuria
SponsorUniversity of Southern Denmark
Conditions studiedDiabetes type2
GLP-1 drugs

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04880005 ↗